MedPath
NMPA Approval

Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed

国药准字SJ20150034

August 13, 2020

S20150034

Drug Information

吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗

潘太欣

注射剂

本品为两个包材包装,其一为百白破脊髓灰质炎疫苗,混悬液,每支0.5ml;其二为b型流感嗜血杆菌结合疫苗,冻干粉。使用前两者混合。其中百白破脊髓灰质炎疫苗含:无细胞百日咳疫苗效价不低于4.0IU;白喉疫苗效价不低于30IU;破伤风疫苗效价不低于40IU;1型灭活脊髓灰质炎病毒40DU,2型灭活脊髓灰质炎病毒8DU,3型灭活脊髓灰质炎病毒32DU;b型流感嗜血杆菌结合疫苗含与破伤风类毒素结合的b型流感嗜血杆菌多糖10μg。

生物制品

August 13, 2020

August 12, 2025

Company Information

Applicant Company

SANOFI PASTEUR

14 Espace Henry Vallee 69007 LYON , France

Manufacturing Company

SANOFI PASTEUR

1541 avenue Marcel Merieux, 69280 MARCY L`ETOILE , France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗 - NMPA 批准文号 | MedPath